Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
News|Videos|May 15, 2023
Various Definitions of Treatment Resistant Depression
Author(s)Lisa Harding, MD
Don't miss this session at the APA 2023 Annual Meeting in San Francisco!
Advertisement
Lisa Harding, MD, shares a preview of her session, "
Check out this session on Saturday, May 20 at 1:30-3:00PM PDT in Room 303, Moscone South.
Dr Harding is an board-certified psychiatrist and intervention specialist in Milford, CT.
Advertisement
Related to this article
Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times’ September 2026 series.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
2
New Real-World Data Supporting Cariprazine for MDD and Bipolar I Depression
3
Pimavanserin Linked to Fewer Falls Than Other Antipsychotics in Parkinson Disease Psychosis
4
Brenipatide for Alcohol Use Disorder: Emerging Findings
5